HTG Molecular Diagnostics Inc(NASDAQ:HTGM) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 9, 2016. Company reported revenue of $1.90M. Analysts estimated a revenue of $1.30M. Earnings per share were $-0.98. Analysts had estimated an EPS of $-0.95.
HTG Molecular Diagnostics Inc (HTGM) made into the market gainers list on Wednesdays trading session with the shares advancing 2.92% or 0.07 points. Due to strong positive momentum, the stock ended at $2.47, which is also near the day’s high of $2.54. The stock began the session at $2.44 and the volume stood at 29,163 shares. The 52-week high of the shares is $13.1 and the 52 week low is $2.03. The company has a current market capitalization of $17 M and it has 70,50,957 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Apr 5, 2016, Shaun D Mcmeans (VP, Finance & Admin. & CFO) sold 1,601 shares at $2.91 per share price.Also, On Apr 5, 2016, Debra A Gordon (V.P. and Chief Legal Counsel) sold 1,672 shares at $2.91 per share price.On Apr 5, 2016, John L Lubniewski (Chief Business Officer) sold 796 shares at $2.91 per share price, according to the Form-4 filing with the securities and exchange commission.
HTG Molecular Diagnostics Inc is a United States-based company that provides products for miRNA and mRNA measurement for translational research/medicine and molecular diagnostics. Its qNPA molecular technology platform is suited for detecting changes in gene expression levels; especially from formalin-fixed paraffin-embedded (FFPE) tissue and other biological sample types. Its products include HTG Edge System HTG Edge Assays and HTG Assay Direct. The HTG Edge System an automated RNA analysis platform that delivers extraction-free multiplexed results on a multitude of biological samples (tissue blood serum cells) in less than 24 hours. HTG Edge DMPK Assay is a 47-gene assay that enables researchers to characterize drug metabolism in pre-clinical studies. HTG Edge Top Oncogene Assay measures the expression levels of 32 of the most commonly assayed oncogenes in fresh or fixed biological specimens.